Valuation dashboard for Silo Pharma, Inc. (SILO) with P/E N/A, P/B 0.39, EV/EBITDA 0.12 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems.
Analysis Summary
Trailing-twelve-month margins: gross margin -474.3%, operating margin -82.5%, net margin -82.7%.
At the current price of $1.76, SILO has negative trailing earnings (P/E not meaningful) and an ROE of -81.74%. Market capitalisation stands at $2M.
Balance sheet quality for SILO: current ratio of 11.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.39 |
| EV / EBITDA | 0.12 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $6.60 |
| vs Current Price | +275.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SILO | Silo Pharma, Inc. | $2M | 0.39 | -81.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.76 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -81.74% |
| Return on Invested Capital | -91.31% |
| Return on Assets | -75.13% |
| Gross Margin | -474.31% |
| Operating Margin | -8250.46% |
| Net Margin | -8269.53% |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · JAGX
Explore sector: Healthcare · Biotechnology
More sections of SILO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks